Volume 130, Issue 5

Cover Figure: Platelet microparticles inhibit tumor growth by transfer of miRNAs. See the article by Michael et al.

WASHINGTON, August 3, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth
In this week’s plenary paper, Michael and colleagues demonstrate that platelet microparticles interact with tumor cells and transfer platelet-derived microRNAs (miRNAs) that downregulate tumor cell gene expression and repress tumor growth.

Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor
Münch et al report that central nervous system (CNS) infiltration by acute lymphoblastic leukemia (ALL) blasts is dependent on leukemia cell expression of vascular endothelial growth factor (VEGF), which modulates the blood-brain barrier. They demonstrate that in ALL xenografted mice, inhibition of VEGF with bevacizumab blocks CNS invasion, elucidating a novel potential targeted approach to preventing CNS relapse.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion
Locatelli and colleagues present the outcome of haploidentical HSCT with αβ T-cell– and B-cell-depleted grafts in 80 children with acute leukemia, reporting outcomes comparable to those of transplants from HLA-identical siblings or matched unrelated donors.

Obinutuzumab: what is there to learn from clinical trials?
In a Perspective, Cartron and Watier discuss the properties of obinutuzumab that distinguish it from other anti-CD20 therapeutics, attributing its distinctive clinical profile to a combination of Fc optimization, complement-binding properties, and dosing regimens.

How I treat double-hit lymphoma
Using two illustrative cases, Friedberg describes his approach to diagnosis and therapy of double-hit lymphomas, including the role of aggressive chemotherapy regimens, CNS prophylaxis, and stem cell transplantation.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome


AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
In two independent reports, Milani et al and Dittrich et al report that AL amyloidosis associated with low free light-chain levels (<50 mg/L) at diagnosis have less cardiac involvement and excellent overall survival in comparison with patients with higher light-chain levels.


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.